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Abstract
Dengue fever (dengue), a mosquito-borne disease caused by dengue viruses (DENVs), 
represents severe public health problems in Southeast Asia, Latin America, Africa and 
other subtropical regions. Many regulatory issues arise along with the development of 
dengue vaccines. It is required to follow the regulatory pathway for the license applica-
tion. Dengue vaccines can be approved without local clinical phase III data. The national 
regulatory authorities (NRAs) must have the information, training and ability to review 
and approve the application. A novel vaccine product Dengvaxia® for dengue has been 
approved in many countries. The approval is based on clinical trials that show the vac-
cine could reduce about 60% dengue, prevented 90% of severe cases and 80% of hospital-
izations. Several other DNA, live-attenuated, purified inactivated, subunit, vectored and 
chimeric vaccine candidates are currently developing in clinical phases. Although there 
are still some challenges for the development and regulation of vaccine, the prospects of 
dengue vaccines are promising provided that we can overcome the difficulty.
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1. Introduction
In this section, we describe some background about dengue fever (dengue).
1.1. Pathogens, vectors and symptoms
Dengue, a mosquito-borne disease, is widespread all over the world in recent years. It is 
caused by the dengue virus (DENV), which is transmitted by female Aedes mosquitoes of spe-
cies A. aegypti and A. albopictus. The mosquito becomes infected when it bites a person with 
DENVs in their blood. DENVs are maintained in cycles that involve blood-sucking vectors 
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and vertebrate hosts. Dengue is transmitted by vectors and is not spread from one person to 
another person directly (Figure 1).
DENV, which belongs to genus Flavivirus of family Flaviviridae, is a small single-stranded 
RNA (ssRNA) virus comprising four distinct but closely related serotypes (DENV-1, 2, 3 and 
4) [1, 2]. However, the fifth serotype DENV-5, which may be produced by genetic recombina-
tion, natural selection and genetic bottlenecks, has been discovered in 2013. This new variant 
follows the sylvatic cycle unlike the other four serotypes, which follow the human cycle [3].
Symptomatic DENV infections were classified into three categories: undifferentiated fever 
(UF), dengue fever (DF, dengue) and dengue haemorrhagic fever (DHF) (also called severe 
dengue). DHF was further classified into four severity grades, with grades III and IV being 
defined as dengue shock syndrome (DSS) [4]. Sometimes, the infection causes flu-like symp-
toms, which are mild, is called UF. DF begins 4–6 days after infection and its symptoms are 
Figure 1. Dengue transmission: Aedes mosquitoes (A. aegypti or A. albopictus) bite a dengue-infected person and suck his 
blood. The mosquitoes ingest blood with dengue viruses and become transmission vectors after 8–10 days. The dengue 
vector mosquitoes bite another unvaccinated healthy person and the person gets dengue 4–13 days later. This may lead 
to endemic transmission if dengue is extensively spread by mosquitoes.
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usually limited. However, serious problems can develop and occasionally result in a lethal 
complication called DHF. The symptoms may further progress to DSS, which is characterized 
by massive bleeding, shock and even lead to death.
Different DENV serotypes may cause a cross-serotypic immune response such as antibody-
dependent enhancement (ADE). ADE is the most widely known example, which occurs in the 
setting of DENV infection. When an individual has been infected with one DENV serotype, 
the antibodies to the previous serotype will interfere with the immune responses to the new 
serotype to lead to more virus attack and entry. The disease varies in severity in humans from 
DF, which is usually limited in symptoms to lethal cases including DHF and DSS.
1.2. Epidemiology
Dengue is one of the most rapidly spreading mosquito-borne viral diseases in the world. 
The number of dengue cases reported annually to WHO increased from 0.4 to 1.3 million 
from 1996 to 2005 and reached 2.2 million and 3.2 million in 2010 and 2015, respectively [5]. 
The disease is currently common in more than 110 countries, mainly in Southeast Asia, Latin 
America, Africa, etc. Infections are usually acquired in the urbans, but they have expanded to 
villages, towns and cities recently.
Most people with dengue recover without any problems. The fatality rate is 1–5%, and less 
than 1% with adequate treatment. Because of urbanization, population growth, frequent 
international travelling and global warming, the incidence rate of dengue increased about 
30-fold from 1960 to 2010 [6]. This disease inflicts a serious healthy, social and economic bur-
den on the people of endemic areas.
1.3. Treatment
The treatment is only supportive and there is no certain treatment for dengue. Current efforts 
are to develop antiviral drugs that would be used for the treatment of dengue and prevention 
of severe complications. There are several plausible therapeutic approaches such as the inhi-
bition of the viral RNA-dependent RNA polymerase inhibitor, viral protease inhibitors, entry 
inhibitors that stop the virus entering cells or inhibitors of the 5′ capping process, which is 
required for viral replication. Supportive care and adjuvant therapy may be needed in severe 
dengue (DHF and DSS).
1.4. Prevention and control
For dengue prevention, traditional method is only restricted to vector control measures. The 
best way is to inhibit the spread of the Aedes mosquitoes and avoid being bitten by them. This 
may be done by eliminating the mosquitoes, removing or covering standing water and wear-
ing clothing that covers the body.
Integrated vector management (IVM) program is a strategy to control vectors recommended 
by the World Health Organization (WHO). IVM considers the following five key elements in 
the management process [5]:
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(1) Advocacy, social mobilization and legislation: The promotion of developmental poli-
cies, the establishment or strengthening of regulatory controls for public health and the 
 empowerment of communities.
(2) Collaboration within the health sector and with others: The consideration of all options 
for collaboration, strengthening communication among policy-makers, program manag-
ers and other key partners.
(3) Integrated approach to disease control: The assurance of the rational use of available re-
sources, integration of non-chemical and chemical control methods and integration with 
other disease control measures.
(4) Decision based on evidence: The adaptation of strategies and interventions to local vec-
tor ecology, epidemiology and resources, guided by operational research and subject to 
routine monitoring and evaluation.
(5) Capacity-building: The development of essential infrastructure, adequate finance and hu-
man resources.
Vaccination is a better measure than the vector control for dengue prevention. The develop-
ment of a dengue vaccine actually represents a great achievement in the control of the disease. 
The impact of dengue is so enormous that its vaccine development is very crucial for public 
health. To develop a dengue vaccine, we have to realize the regulation requirements of vac-
cines such as basic research, animal studies and clinical trials, etc.
2. Regulation
Dengue vaccines, as all vaccine products regulated by national regulatory authorities (NRAs) 
and national control laboratories (NCLs), undergo a rigorous review of laboratory and clinical 
data to ensure their safety, efficacy and potency. The discovery and application of dengue vac-
cines should follow the frame work of vaccine research and development. The manufacturer 
has to comply with the related regulation, including nonclinical work, preclinical trials, human 
clinical trials and post-market surveillance [7]. In this section, we review the regulations that 
are specific and required for dengue vaccines, including basic requirements, regulatory path-
ways, special procedures, regulatory requirement summary and regulatory challenges.
2.1. Basic requirements
The WHO Initiative for Vaccine Research (IVR) focuses on the following objectives for dengue 
vaccine development:
(1) Knowledge and research: Identification of knowledge gaps and research need to be  related 
to the development, evaluation and implementation of dengue vaccines.
(2) Consensus and guidance: The scientific consensus for dengue control and guidelines on 
the evaluation of dengue vaccines need to be established.
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(3) Review and evaluation: The evidence base for the policy recommendations related to the 
introduction of dengue vaccines need to be reviewed and evaluated previously.
(4) Vaccination program: The guidance and program on dengue vaccine administration, in-
cluding implementation strategies need to be strictly conducted.
(5) Support of NRAs: The NRAs should be assisted and encouraged in the review of dengue 
vaccine registration files.
2.2. Regulatory pathways
The regulators of developing countries and developers for dengue vaccines had two meetings 
in 2007. The first meeting with Developing Countries’ Vaccine Regulators Network (DCVRN) 
was held on April 2007 in Brazil [8]. Their topics included the nature and epidemiology of the 
dengue fever, the status of dengue vaccine development and the regulatory issues needed to 
be addressed. The second meeting was held in Thailand on December 2007 and several den-
gue vaccine developers participated in this meeting [8]. Each of these companies presented 
the development status of their candidates and outlined the issue that they regard important 
for testing and want ultimate regulatory approval of these vaccines. The summary points for 
their meeting report are as follows [8]:
(1) Regulatory agencies need to address some issues related to multivalent vaccines because a 
dengue vaccine is tetravalent and provide protection against all the four DENV serotypes.
(2) The potential risk of inducing antibody-enhanced diseases such as ADE should be veri-
fied by long-term safety assessment.
(3) Dengue vaccines need to be assessed in diverse populations because the epidemiology 
and impact of dengue are varied in different countries.
(4) The NRAs in developing countries may be involved in review of the applications of 
clinical evaluation and the marketing of vaccines and they should receive support as 
appropriate.
(5) Manufacturers must submit a dossier to the NRAs for review.
(6) The NRAs need to have access to the necessary expertise to review the quality and safety 
of dengue vaccines and consider accelerating their introduction.
(7) The improved standardized tests should be introduced for the diagnosis of early infection 
and for the measurement of immune protection.
On October 2009, WHO and the Pediatric Dengue Vaccine Initiative (PDVI) convened a meet-
ing in Thailand. The topics covered in this meeting considered the interactions between sci-
entific regulatory reviews and ethics committee reviews of applications to undertake clinical 
trials of dengue vaccines. Their main conclusion was that it would be better if scientific and 
ethical reviews can work together well, but there was no alteration in scientific or technical 
views about the regulation of dengue vaccines.
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On October 2011, WHO convened a consultation of experts in dengue vaccine regulations to 
review the current scientific data regarding safety concerns associated with the live attenu-
ated dengue vaccine. It was emphasized that a complete plan and a suitable method for long-
term safety assessment are required to ensure the introduction and continuous application of 
dengue vaccines.
On July 2016, WHO issued a position paper to mention that countries are encouraged to estab-
lish a functional pharmacovigilance system to monitor and manage adverse reactions follow-
ing immunization when dengue vaccines were introduced. Countries considering vaccination 
should also have a dengue surveillance system which is capable of detecting  hospitalization 
and severe dengue cases consistently [5].
2.3. Special procedures
At the dengue vaccine development stage, some clinical trials can be omitted, although many 
issues regarding implementation of dengue vaccines still need to be addressed. For example, 
a dengue vaccine can be approved without local clinical phase III data but adopt other coun-
try’s data in some countries such as Indonesia. Some vaccine candidates have progressed 
from animal trials directly to human clinical phase II and III in some countries such as India.
2.4. Summary of regulation requirements
It is crucial to select suitable sites for clinical trials of dengue vaccine candidates. The key con-
sideration for selecting sites in developing countries where dengue is endemic includes inves-
tigator experience, DENV prevalence, NRA competence, the implications between rural and 
urban sites, acquisition of multi-year data on dengue incidence and the ability to detect clini-
cal dengue cases. The PDVI is working with these sites in developing countries to enhance 
their capabilities to undertake clinical studies and safety surveillance. Many important issues 
have been identified for regulatory review of dengue vaccines. Plans are being developed to 
provide appropriate training to the NRAs to build their review capacity. Based on the results 
of the PDVI/DCVRN meetings on dengue vaccines, the regulation requirement of dengue 
vaccines is summarized as follows [8, 9]:
(1) Diligent safety surveillance: Because of possible immune enhancement in individuals 
who are only partially immunized and become naturally infected or who have been pre-
viously infected and receive a first vaccine dose, it is required to frequently monitor the 
safety of dengue vaccines in the initial stages of clinical trials. Improved definitions of 
adverse events following immunization are needed. In addition, methods to detect these 
events should be validated. It is necessary to perform improved safety surveillance and 
early viral analysis in cases of dengue fever.
(2) Assurance a favourable risk-benefit for the specific country: The NRAs in dengue-prev-
alent countries must consider new approaches to accelerate vaccine development. They 
will be requested to discuss on licensure of a tetravalent dengue vaccine with demonstrat-
ed efficacy and safety against only one DENV serotype. However, under this condition, 
post-marketing surveillance for safety and efficacy against all four serotypes is required.
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(3) The vaccines used in testing and clinics should be the same: Vaccines being tested in 
subsequent studies should be the same as those being used in earlier clinical stages. Any 
changes in manufacturing processes or formulation are critical and could result in the 
need to repeat the clinical trials or require complex studies.
(4) “Standard definitions” should be commonly understood: Standardized testing methods 
for antibody responses and virus typing are essential, especially for laboratory-based 
serological tests. The validated international reference standards need to be established. 
In addition, phase IIa, phase IIb and phase III trials should be clearly defined.
(5) An animal model is not necessarily required: The development of an animal model 
would be of great benefit but likely not essential for licensure. Clinical trials could pro-
vide data to help the NRAs to understand the science of the possible severe immune-en-
hanced disease and identify correlates of immunity/protection that would assist vaccine 
development.
(6) Characteristics of clinical trial design should be defined: An effort to design clinical trial 
and consult the NRAs is the duty of the vaccine manufacturers. These issues include 
target age group for immunization, vaccine dosage schedule, trial duration and follow-
up, possible immune responses to other flaviviruses, diagnosis and case definition and 
long-term safety surveillance. Additional considerations for assessing potential trial sites 
include the prevalence of the viral strains, influence of concurrent mosquito control pro-
grams, community involvement, and virological and diagnostic services.
(7) Phase III trials data can be conditionally omitted: For vaccine approval, the responsi-
ble NRAs need to establish special procedures to review and accept other country data. 
Phase III trials may be undertaken in some countries based on the safety and efficacy data 
from Phase II (a or b) trials in other countries.
(8) Joint review of license applications is recommended: The DCVRN prefers the formal 
procedures for collaboration and joint review of clinical trial monitoring including good 
clinical practice (GCP) inspections by the responsible NRAs, European Medicine Agency 
(EMA) and/or United States Food Drug Administration (US FDA) with facilitation by 
WHO. The NRAs would need to have access to the necessary expertise and advisory 
committee to review the quality, efficacy and safety aspects of the license application.
2.5. Regulatory challenges
The development of dengue vaccines in developing countries has been recently accelerated 
due to the substantial funding increase from public institutions and private sources. Along 
with the progress of vaccine development, two complex regulatory issues arise as follows [8]:
(1) Clinical trials data are limited in developing countries: Dengue is prevalent only in tropi-
cal countries where there is poor public health. It is almost impossible to perform clinical 
trials for dengue vaccines in developed countries. Clinical trials to assess the safety and 
efficacy of dengue vaccines are usually carried out in developing countries where dengue 
is prevalent, and the first licensure of dengue vaccines will occur there.
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(2) Regulatory review and license approval are challenging in developing countries: It is re-
quired to ensure that developing countries have the ability to undertake appropriate reg-
ulatory review of proposed clinical studies and of applications for licensure. The NRAs of 
these developing countries must have the information, training and capabilities to review 
clinical trials and approve applications eventually.
3. Product
In this section, we introduce the newly licensed dengue vaccine in endemic countries and 
some developing dengue vaccines based on the regulation requirements.
3.1. Philosophy of development
Dengue has become an increasing threat around the world along with the transmission of 
the disease-carrying mosquitoes and the itinerary to dengue-endemic areas. To reduce the 
social and economic burden of dengue, before 2020, WHO aims to decrease the overall den-
gue mortality and morbidity by 50 and 25%, respectively. In the absence of specific antiviral 
therapy, effective vector control is the only strategy to mitigate the incidence rate of den-
gue. Vector control interventions have not been satisfied in reducing dengue transmission 
due to increasing rural-urban migration, rapid population growth, unplanned urbanisa-
tion and insecticide resistance in mosquitoes. The need for an effective dengue vaccine is 
obvious because a safe, efficacious and economic dengue vaccine can be a supplementary 
measure for dengue prevention and control. Vaccine development focuses on the genera-
tion of a tetravalent vaccine to provide long-term protection against the four DENV sero-
types (DENV-1, 2, 3 and 4). Additionally, vaccination of target groups such as travellers 
and migratory population may be a suitable strategy to prevent the spread of dengue to 
non-endemic areas or dengue-free regions. However, there was no commercially available 
dengue  vaccine before 2015.
3.2. Successful product: Dengvaxia®
The first dengue vaccine, known as Dengvaxia® (CYD-TDV) by Sanofi Pasteur, was registered 
in Mexico on December 2015 and has been licensed in many countries, including Mexico, 
Brazil, Philippines, El Salvador, Costa Rica, Guatemala, Peru, Indonesia, Paraguay and 
Singapore till 2016. It is approved for use for those aged 9–45 and recommended to prevent 
four DENV serotypes (DENV-1, 2, 3, and 4) [10–12].
The significant reduction in disease burden using Dengvaxia® has been demonstrated in 
recent research. For individuals that have been already exposed to at least one DENV, the 
vaccination program is most effective. Immunological screening of the population prior to 
vaccination is recommended. When the vaccine is given only to partial immune individuals, 
disease burden decreases considerably. Vaccination strategies must be planned based on epi-
demiological disease dynamics for each specific endemic region [10].
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3.3. Production of Dengvaxia®
Dengvaxia® is designed to induce the immune system to produce antibodies against all four 
DENV serotypes (DENV-1, 2, 3, and 4). It is a live attenuated tetravalent chimeric vaccine 
developed using recombinant DNA technology by replacing the PrM (pre-membrane) and 
E (envelope) structural genes of the yellow fever live attenuated vaccine [10, 11]. For the vac-
cine, the virus is genetically engineered to include genes encoding for dengue proteins. Its 
production is based on a weakened combination of the yellow fever virus and each of the four 
DENV serotypes.
3.4. Efficacy of Dengvaxia®
Dengvaxia® was given as a three-dose series on a 0/6/12 month schedule and has been evalu-
ated in two Phase III clinical trials. The results have been proved for each trial and pooled. 
The recent research has found that the vaccine was effective in reducing about 60% dengue, 
65.6–81.9% hospitalization and in preventing 80–90% of DHF cases in individuals 9-45 years 
old [2, 10, 11].
3.5. Disadvantages of Dengvaxia®
The transmission dynamic model and clinical trial data have demonstrated that Dengvaxia® 
effectiveness depends mainly on the age group vaccinated and local transmission intensity 
[10]. Therefore, the new vaccine still has some disadvantages as follows:
(1) Reduction rate is low: In clinical trials, the vaccine only reduced the chances of develop-
ing the disease by about 60%.
(2) Not effective for all ages: The vaccine is only approved for use in people 9–45 years old. 
In fact, the vaccine seems to be least effective in children younger than 9 who need the 
vaccines most.
(3) Side effects possibly occur: Vaccinated individuals potentially have more severe cases of 
dengue if they contact DENVs later in life.
3.6. Developing products
Several other DNA vaccine, live-attenuated vaccine, inactivated vaccine, subunit vaccine and 
chimeric vaccine candidates are being developed at early stages of clinical trials by some 
manufacturers (Table 1) [13–15]. Other vaccines using virus vectors and virus-like particles 
(VLP) are being evaluated in preclinical studies [15].
(1) DNA vaccine: DNA vaccine candidates have been used to induce cellular immunity 
against various antigens using in vitro or animal models. This technology is based on 
cloning a specific gene into a bacterial plasmid containing a strong promoter for expres-
sion in mammalian cells.
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(2) Live-attenuated vaccine: Live attenuated vaccine candidates, made of weakened viruses, 
are excellent immunogens because they can induce both humoural and cellular immune 
responses similar to a natural infection, but their virulence is not enough to cause diseases.
(3) Inactivated vaccine: Inactivated vaccine candidates, made from viruses inactivated by 
heating or formaldehyde, are safer than live-attenuated candidates because of their in-
ability of virulence reversion and no harm to immunocompromised individuals. A syner-
gistic formulation with another live attenuated vaccine candidate (prime-boost strategy) 
is being evaluated.
(4) Subunit vaccine: Recombinant subunit vaccine candidates, made of viral protein subu-
nits, have wider safety profile. They will not produce the same immune responses as 
live attenuated vaccines because they contain only one or few viral proteins. The DENV 
envelope protein is the most immunogenic and usually used for vaccine production.
(5) Chimeric vaccine: Chimeric yellow fever/dengue virus vaccine candidates are the most 
advanced vaccine, being evaluated on large-scale clinical trials worldwide. These are cat-
egorised as follows:
a. The chimeric live attenuated DENV-2/DENV vaccine (DENVax): The DENVax was 
constructed using the backbone of attenuated DENV-2 (PDK-53 strain) in cell culture, 
in which the prM and E genes of DENV-2 PDK-53 were substituted for those of wild-
type DENV-1, 3 or 4.
b. The chimeric live attenuated DENV/DENV vaccine (TetraVax-DV): The TetraVax-DV is 
a tetravalent vaccine candidate for which attenuation was achieved by deleting 30 nu-
cleotides on 3′ untranslated region of wild-type DENV-1 and DENV-4. This approach 
did not result in any attenuation for the other two serotypes: DENV-2 and DENV-3.
(6) Vectored vaccine: The vectored vaccine candidates, a recombinant poxviruses and adeno-
viruses expressing foreign proteins, have been demonstrated to induce strong humoural 
and cellular responses in humans. Several live virus vectors such as adenovirus, alphavi-
rus and vaccinia virus have been engineered to express DENV E protein for further evalu-
ation as dengue vaccine candidates.
3.7. Challenges of vaccine development
Though Dengvaxia® has been successfully developed and licensed in many countries, dengue 
vaccine development is time-consuming, costly and difficult. The following challenges are 
still ahead of us for the development of new dengue vaccines [15, 16].
(1) Restriction of virus growth: The DENV is growing poorly in cell culture.
(2) Limitation in immunization: Infection by one of the four DENV serotypes will provide 
lasting protection against homotypic reinfection, but only transient protection against a 
secondary heterotypic infection.
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(3) Incidence of antibody-enhanced diseases: The existence of four distinct DENV serotypes 
is capable of eliciting cross-reactive and ADE against the remaining three serotypes.
(4) Lack of an animal model: A suitable animal for dengue vaccine studies is currently not 
available and may result in uncertainty for the correlates of protection.
(5) Variation of the efficacy evaluation data: The neutralising antibody response to a specific 
DENV serotype is traditionally detected by plaque reduction neutralisation test (PRNT), 
but PRNT variations often occur in the collaborative studies. The variation may account 
for erroneous results in vaccine efficacy evaluation. Standardised guidelines need to be 
established by regulatory bodies like WHO for conducting PRNT.
(6) Complexity of tetravalent vaccines: Dengue is mainly caused by four DENV serotypes; 
thus, an effective dengue vaccine must be tetravalent. Theoretically, it is possible for in-
ducing immune responses in individuals not protected against all four serotypes. How-
ever, the tetravalent vaccine development is difficult and complicated because of interfer-
ence among the viruses.
(7) Emergency of more DENV serotypes: Discovery of DENV variants such as a sylvatic 
strain DENV-5 may impede the dengue vaccine initiative. Further genetic variability, 
ecology and epidemiology studies of these new strains are needed for the effective den-
gue vaccine development.
4. Perspectives
For successful vaccine introduction, it is essential to have early preparation and understand-
ing of the true burden of dengue. Although a licensed dengue vaccine-Dengvaxia® has been 
available, there is need to ensure that appropriate surveillance is maintained to monitor 
its efficacy, safety and effectiveness during the post-licensure period. An evidence-based 
Vaccine candidate DEN-Vax TetraVax-DV TDEN PIV V180
Type Chimeric vaccine Chimeric vaccine Inactivated vaccine Subunit vaccine
Trait A recombinant 
chimeric vaccine 
with DENV-1, 3 and 
4 components on 
DENV-2 backbones
A tetravalent 
admixture of 
monovalent vaccines 
that were tested 
separately for safety 
and immunogenicity
An inactivated 
tetravalent vaccine
A recombinant 
subunit vaccine 
expressed in 
Drosophila cells
Ongoing clinical trial Phase I and II Phase I and II Phase I and II Phase I
Testing country, 
company or institute
United States, 
Colombia, Puerto 
Rico, Singapore and 
Thailand
Thailand and Brazil GSK and the Walter 
Reed Army Institute 
of Research
Merck
Table 1. Dengue vaccine candidates under development and on clinical trials.
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approach is recommended to enhance and harmonize critical characteristic of dengue vac-
cines including case classification, data analysis and laboratory testing. The strengthening 
vaccination policy will require more investment in current public health systems; further-
more, R&D, advocacy and regulation requirements of vaccines should be emphasized. The 
increasing knowledge and technology will provide more insights to improve vaccine design 
and quality. If the following prospective comes true, the effect and impact of dengue vaccines 
will be significant.
4.1. Enhancement of efficacy and safety
Vaccine efficacy against dengue seemed to vary according to the serotype of the infecting 
DENV [17]. Additional pooled efficacy, integrated safety analyses from the clinical phase III 
efficacy studies and the ongoing safety studies should be used to confirm the efficacy and 
longer term safety of dengue vaccines.
4.2. Enlargement of preventive age range
In recent studies, age-related patterns for dengue vaccine efficacy were observed in the pooled 
estimated efficacies against severe dengue [17]. The prevention of dengue infection caused by 
four DENV serotypes in individuals mainly aged 9–45 years. It would be better if the vaccine 
can be improved to provide significant protection to those whose age is below 9 and over 45.
4.3. Improvement of quality control
The quality control of dengue vaccines is as important as the evaluation of their efficacy. 
Dengue vaccines currently are not included in any pharmacopoeia. Their production, char-
acterization, identification, test and assay should be defined in the official pharmacopoeia. 
Vaccine manufacturers, testing laboratories and the NRAs must strictly follow the compen-
dial definition, methods and guidance.
4.4. Development of multivalent vaccines
If someone exposes to only one DENV serotype and specific immunity is induced to protect 
against this serotype, the individual protected against only one serotypes may be subjected 
to a severe immune response such as ADE once the individual exposes to the other serotypes. 
The major hindrance of dengue vaccine development is the complex immune responses to 
DENVs and the difficulty in eliciting concomitant protection against all distinct DENV sero-
types. It would be the best to develop a multivalent vaccine against all the DENV serotypes 
including DENV-1, 2, 3, 4 and 5 or more, not only restricted to some serotypes.
4.5. Implementation of post-market surveillance
The dengue vaccine should be closely monitored to ensure its persistent efficacy and safety 
after marketing. The vaccine approved for clinical application may be required to perform 
additional studies to give further evaluation and often address specific questions such as 
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safety, efficacy or possible side effects and contraindications. Local and global capacity for 
assessing the long-term safety of the dengue vaccine in post-licensing surveillance must be 
strengthened to meet the challenges imposed by its potentially complex performance [17].
4.6. Revision or enactment of related regulations
Regulatory requirements of dengue vaccine must be flexible and specific in developing coun-
tries. Continuous revision or enactment of guidelines, regulations and laws for dengue vac-
cines is needed to expedite new vaccine discovery. Conditional license approval should be set 
up and clearly defined in that the dengue transmission is diverse in different countries and 
local areas. In addition, the mechanisms of professional review and international cooperation 
for vaccine clinical application must be established.
5. Conclusions
Although many developmental and regulatory challenges are confronted, the dengue vaccine 
discovery is rapid and efficient. The product Dengvaxia® has been approved in several coun-
tries and a number of vaccine candidates are being developed in different phases of clinical 
trials. Efficacy of the vaccine candidates is variable due to varying epidemiology of the disease 
in diverse populations. The situation may further be complicated by the emergency of a new 
serotype of DENV such as DENV-5 which is different from the original four serotypes (DENV-
1, 2, 3 and 4) was isolated. Sustained transmission of a new serotype may become another 
obstacle in the future development of dengue vaccines. Hence, it is required to strengthen the 
surveillance of the disease prior to any dengue vaccine is introduced into the clinical appli-
cation. The safety of vaccines in clinical trials should be evaluated for longer period of time 
and larger populations should be involved because of its potential risk of inducing immune 
enhancement such as ADE. In addition, it is urgent to develop and standardise diagnostic 
approaches for better prediction of the protective immune responses in dengue.
Regulations are the most important criteria for the development and marketing of dengue 
vaccines. Regulatory science is evidence-based and any improvement or change should be 
dependent on scientific data. Therefore, more epidemiological and clinical data for DENV 
are essential for dengue vaccine research and development (R&D). Continuous revision or 
establishment of flexible and specific laws, regulations and guidance for dengue vaccines 
will expedite new vaccine discovery. Dengue is usually prevalent in developing countries 
with diverse social, cultural, economic and scientific development. Also, the dengue epide-
miology and disease burden are quite different in these countries. Every country has specific 
conditions for dengue transmission, prevention and control, regulations for dengue vaccines 
should be enacted and implemented in accordance with the needs of individual countries and 
the situation of local circumstances.
In spite of some limitations, the collaborative effects of regulatory bodies such as WHO, 
PDVI and policy makers with vaccine manufacturers to facilitate vaccine R&D and standard-
ize field trials are significant. The NRAs are working together to cooperate with the vaccine 
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manufacturers to accelerate dengue vaccine development and standardise their testing. The 
current object is to strengthen the dengue surveillance network, explore the social and eco-
nomic burden of dengue, identify clinical trial areas and support basic research to produce 
safe and effective dengue vaccines. In the near future, dengue vaccination may become an 
effectively preventive measure to substitute for vector control to suppress the increasing 
global burden of dengue.
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